

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/160395 A1

(51) International Patent Classification:

A61K 31/501 (2006.01) C12N 9/22 (2006.01)
A61K 31/519 (2006.01) C12N 15/10 (2006.01)
A61K 31/522 (2006.01)

(21) International Application Number:

PCT/US2025/012952

(22) International Filing Date:

24 January 2025 (24.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/625,090 25 January 2024 (25.01.2024) US
63/655,679 04 June 2024 (04.06.2024) US

(71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400
Dexter Avenue North, Suite 1200, Seattle, Washington
98109 (US).

(72) Inventors: MU, Yucheng; Route 206 and Province Line
Road, Princeton, New Jersey 08543 (US). QIAO, Jen-
nifer X.; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). MENG, Yilin; Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).
D'AGOSTINO, Laura Akullian; 27 Hopestill Brown
Road, Sudbury, Massachusetts 01776 (US). CLEYRAT,
Cédric; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). THELEN, Ashley; Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).
FERNANDEZ, Jenna; Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(74) Agent: BANINI, Serge et al.; Mintz Levin Cohn Ferris
Glovsky & Popeo, P.C., One Financial Center, Boston,
Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION
OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING



(I),



(II),

(57) Abstract: The present disclosure is directed to compositions comprising DNA-PK inhibitors having the Formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof and PolQ inhibitor Compounds for Formula (II), methods of preparing the forgoing, as well as methods of use for said compositions.

WO 2025/160395 A1